Black Diamond Therapeutics Receives 'Moderate Buy' Rating from Analysts

The biotech company's stock has a consensus recommendation and average target price from Wall Street analysts.

Apr. 12, 2026 at 6:49am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate gears, levers, and metal components of a complex financial machine, representing the inner workings of the banking and investment industry.Black Diamond Therapeutics' stock performance and pipeline progress will be closely monitored by the financial industry as the biotech company continues its work on precision cancer treatments.Cambridge Today

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) has received a consensus rating of 'Moderate Buy' from the eight analysts currently covering the firm, according to MarketBeat. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, and five have assigned a buy recommendation. The average 12-month target price among analysts is $9.83.

Why it matters

This consensus 'Moderate Buy' rating and average target price from Wall Street analysts provide insight into the current sentiment and expectations around Black Diamond Therapeutics, a clinical-stage biotech company focused on developing precision oncology treatments.

The details

Several brokerages have recently weighed in on BDTX stock. Piper Sandler lowered their target price from $9 to $8 and maintained an 'overweight' rating. Zacks Research cut the stock from 'strong-buy' to 'hold'. Wedbush upped their price objective from $13 to $14 and kept an 'outperform' rating.

  • Black Diamond Therapeutics released its latest earnings report on March 16, 2026.

The players

Black Diamond Therapeutics, Inc.

A clinical-stage precision oncology company focused on developing small-molecule therapies that target oncogenic proteins with tumor-driving mutations.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

This consensus 'Moderate Buy' rating from Wall Street analysts suggests cautious optimism around Black Diamond Therapeutics' pipeline of precision oncology treatments, though the company's stock price and performance will continue to be closely watched by investors.